Sugi Predict

Sugi Predict / Compounds / SCHEMBL17847947

SCHEMBL17847947

SCHEMBL17847947

CC(C)(C)OC(=O)N1CCc2cnc(Cl)nc2C1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.54
▸ ESR2 Q92731 1/20 0.52
▸ NR1H2 P55055 2/20 0.48
▸ DDB1 Q16531 1/20 0.45
▸ CRBN Q96SW2 1/20 0.45
▸ MAPK1 P28482 5/20 0.42
▸ PARP1 P09874 1/20 0.41
▸ TNKS2 Q9H2K2 1/20 0.41
▸ PARP2 Q9UGN5 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAP3K5 Q99683 2/20 0.41
▸ CDK2 P24941 2/20 0.39
▸ MKNK1 Q9BUB5 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CKS1B P61024 1/20 0.38
▸ SKP1 P63208 1/20 0.38
▸ SKP2 Q13309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17183931 0.90 MAPT (0.65) MAPTESR2NR1H2DDB1CRBN
SCHEMBL29757600 0.90 MAPT (0.65) MAPTESR2NR1H2DDB1CRBN
SCHEMBL15875047 0.88 DDB1 (0.53) MAPTESR2NR1H2DDB1CRBN
SCHEMBL31073472 0.86 MAPT (0.55) MAPTESR2NR1H2DDB1CRBN
SCHEMBL22803887 0.85 NR1H2 (0.54) MAPTESR2NR1H2DDB1CRBN
SCHEMBL22993245 0.84 MAPT (0.51) MAPTESR2NR1H2DDB1CRBN
SCHEMBL29388436 0.84 MAPT (0.51) MAPTESR2NR1H2DDB1CRBN
SCHEMBL27233890 0.84 MAPT (0.53) MAPTESR2NR1H2DDB1CRBN
SCHEMBL3133107 0.83 MAPT (0.52) MAPTESR2NR1H2DDB1CRBN
SCHEMBL22980530 0.83 MAPT (0.52) MAPTESR2NR1H2DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132132-A1 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2026-05-14 — — US disclosed
US-12448389-B2 BRM targeting compounds and associated methods of use PRELUDE THERAPEUTICS INCORPORATED (US) 2025-10-21 — — US disclosed
US-20250276966-A1 Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2025-09-04 — — US disclosed
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 — — US disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20250051347-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals, Inc. (CN) 2025-02-13 — — US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 — — CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 — — EP disclosed
CN-115594669-B Parallel ring derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-11-05 — — CN disclosed
CN-118184657-A PARP7 inhibitor and preparation method and application thereof 成都先导药物开发股份有限公司 2024-06-14 — — CN disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 — — US disclosed
US-20210300947-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-09-30 — — US disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
CN-112313228-A Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2021-02-02 — — CN disclosed
EP-3233858-B1 ERK INHIBITORS MERCK SHARP & DOHME (US) 2019-10-30 — — EP disclosed
US-9884048-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-06 — — US disclosed
EP-3233858-A1 ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-25 — — EP disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 — — US disclosed
WO-2016100050-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132132-A1 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS F11, F13B, F7 MAPT 4849/4885ESR2 2561/4885NR1H2 1619/4885
US-20170266167-A1 ERK INHIBITORS MAPK1, MAPK3, MAPK6 MAPT 2499/4885ESR2 1039/4885NR1H2 658/4885
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAPT 3323/4885ESR2 447/4885NR1H2 456/4885
US-20210300947-A1 NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE SSB, UACA, HLA-DRB1 MAPT 4651/4885ESR2 3865/4885NR1H2 759/4885
US-20250276966-A1 Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives CCNI, MKI67, CCNA1 MAPT 4791/4885ESR2 2318/4885NR1H2 4554/4885
US-20250051347-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER AR, ADRM1, MDM2 MAPT 245/4885ESR2 504/4885NR1H2 562/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 MAPT 3548/4885ESR2 2034/4885NR1H2 794/4885
US-12448389-B2 BRM targeting compounds and associated methods of use ADRM1, BRDT, RBX1 MAPT 1598/4885ESR2 563/4885NR1H2 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.